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 Inflammatory molecules have been identified in experimental models of epilepsy and 
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 Targeting these pathways results in anti-ictogenesis, anti-epileptogenesis and/or disease- 
modifying effects 
 Therapeutic approaches against inflammatory mechanisms could represent novel 
avenues for drug development in epilepsy 
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Abstract 
A large body of evidence that has accumulated over the past decade strongly supports 
the role of inflammation in the pathophysiology of human epilepsy. Specific inflammatory 
molecules and pathways have been identified that influence various pathologic outcomes 
in different experimental models of epilepsy. Most importantly, the same inflammatory 
pathways have also been found in surgically resected brain tissue from patients with 
treatment-resistant epilepsy. New anti-seizure therapies may be derived from these novel 
potential targets. An essential and crucial question is whether targeting these molecules 
and pathways may result in anti-ictogenesis, anti-epileptogenesis and/or disease-
modification effects. Therefore, preclinical testing in models mimicking relevant aspects 
of epileptogenesis is needed to guide integrated experimental and clinical trial designs. 
We discuss the most recent preclinical proof-of- concept studies validating a number of 
therapeutic approaches against inflammatory mechanisms in animal models that could 
represent novel avenues for drug development in epilepsy. Finally, we suggest future 
directions to accelerate preclinical to clinical translation of these recent discoveries.  
 
KEY WORDS: Inflammation, Immune response, Drug development, Anti-ictogenesis, 
Anti-epileptogenesis, Disease-modification, Epilepsy 
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Introduction 
There is an urgent need for the development of new drugs for patients with drug-resistant 
epilepsy. In particular, anti-epileptogenesis or disease-modifying therapies for preventing 
or delaying the onset of the disease are still missing. In the last decade an increasing 
body of clinical and experimental evidence supports the role of inflammation in the 
pathophysiology of epilepsy.1 In particular, different inflammatory molecules and 
pathways have been shown to significantly contribute to the mechanisms of seizure 
generation and progression in different experimental models.2-6  
Here, we summarize presentations concerning targets and treatments validated in 
experimental models [i.e., Cyclooxygenase-2 (COX-2), Prostaglandin (PG) EP2 receptor, 
Monoacylglycerol lipase (MAGL), Interleukin-(IL) High Mobility Group Box 1 
(HMGB1)/Toll-like receptor (TLR) signaling, P2X7 receptor, Immunoproteasome, 
Mammalian target of rapamycin (mTOR), Transforming Growth Factor- , 
Metalloproteinases, Chemokines; Fig. 1]. We will discuss strategies related to target 
validation, controversies and open questions that may hopefully help to improve research 
efforts for novel drug development and foster more coordinated experimental and clinical 
trial designs. 
COX-2, PGE2 and MAGL  
(W. Löscher, R. Dingledine, G. Terrone) 
The enzyme COX-2, which catalyzes the production of prostaglandins, is induced rapidly 
and strongly in the brain after various insults, thus contributing to brain inflammatory 
processes involved in the long-term consequences of such insults. The use of selective 
COX-2 inhibitors has been considered as a novel approach for anti-epileptogenesis or 
disease-modification after brain injuries such as head trauma, cerebral ischemia or status 
epilepticus (SE).7 Accordingly, conditional ablation of COX-2 limited to forebrain neurons 
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is neuroprotective and reduces brain inflammation after SE.8 Löscher discussed 
previously reported conflicting results related to prophylactic administration of different 
COX-2 inhibitors after SE in rodents. Jung et al. 9 showed that prolonged administration 
of the COX-2 inhibitor celecoxib after pilocarpine-induced SE in rats prevents neuronal 
damage in the hippocampus and reduces incidence, frequency and duration of 
spontaneous recurrent seizures, indicating an anti-epileptogenic or disease-modifying 
effect in this post-SE model of temporal lobe epilepsy. In apparent contrast to the study 
of Jung et al.9, Holtman et al.10 did not find any evidence of anti-epileptogenic, disease-
modifying or neuroprotective effects of prolonged treatment with another COX-2 inhibitor, 
SC58236, after electrically-induced SE. Similar experiments were performed by 
Polascheck et al.11 , using parecoxib, a prodrug of the highly potent and selective COX-2 
inhibitor valdecoxib, because celecoxib has been reported to exert also COX-2 
independent actions. Using an electrical model of SE, Löscher and colleagues partially 
confirmed the findings of Jung et al.9 in the pilocarpine model, thus allowing to evaluate 
which experimental factors may affect the outcome of such studies. Prophylactic 
treatment with parecoxib prevented the SE-induced increase in PGE2 and reduced 
neuronal damage in the hippocampus and piriform cortex. However, the incidence, 
frequency or duration of spontaneous seizures developing after SE or the behavioral and 
cognitive alterations associated with epilepsy was not affected by parecoxib. Only the 
severity of spontaneous seizures was reduced, suggesting a disease-modifying effect. 
These results substantiated that COX-2 contributes to neuronal injury developing after 
SE, but inhibition of COX-2 does not appear to provide an effective strategy to modify 
epileptogenesis. This implies that neuroprotective strategies alone after SE are unlikely 
to affect epileptogenesis. In view of the complexity of the inflammatory alterations after 
brain insults such as SE, it is more likely that a multi-targeted combination of different 
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anti-inflammatory drugs is needed for efficient control of the pathologic inflammatory 
cascade. Indeed, Kwon et al. 12 studied combinations of anti-inflammatory drugs in the 
pilocarpine model in developing rats (2-3 weeks of age) and found that none of these 
drugs affected epilepsy when administered alone, whereas the blockade of IL-1 receptor 
type 1 (IL-1R1) using anakinra and the concomitant COX-2 inhibition greatly reduced the 
development of spontaneous recurrent seizures and limited the extent of CA1 injury and 
mossy fiber sprouting. However, treatment started shortly before SE induction, so that it 
is not clear whether the effects of treatment were due to initial insult modification or to 
genuine antiepileptogenesis. More recently, Citraro et al. 13 reported that early long-term 
treatment with the COX-2 selective inhibitor etericoxib reduced by ~40% the development 
of spontaneous absence seizures in WAG/Rij rats, a recognized animal model of 
absence epilepsy. The latter finding could either indicate that COX-2 is more critical in 
epileptogenesis underlying absence epilepsy than in temporal lobe epilepsy or, more 
likely, post-SE models of epilepsy are too severe to disclose anti-epileptogenic effects of 
COX-2 inhibitors.  
Notably, several COX-2 inhibitors have been withdrawn from the market due to cardiac 
events.14 Therefore, an alternative strategy to increase target selectivity with milder 
adverse event profile, might be achieved by a drug acting on a downstream prostanoid 
receptor. Because PGE2 is a major product of COX-2 in the brain, and two of its 
receptors, EP1 and EP2, have been implicated in neuronal injury and inflammation in 
other disorders15, Dingledine and colleagues focused on these two prostanoid receptors. 
A higher dose of systemic kainate was required to produce SE in EP1 knockout mice 
(KO) compared to wild-type (WT) controls, but EP1 KO mice that did experience typical 
SE had reduced hippocampal neurodegeneration and a blunted inflammatory response 16 
Because this is a global KO, the location of the responsible EP1 receptors is, of course, 
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unspecified by this experiment. Co-expression of recombinant EP1 and kainate receptors 
in cell cultures demonstrated that EP1 receptor activation potentiates heteromeric but not 
homomeric kainate receptors via a second messenger cascade involving phospholipase 
C, calcium and protein kinase C. Turning to EP2, Dingledine and colleagues used high 
throughput screening and medicinal chemistry to develop a small molecule acting as EP2 
competitive antagonist that is potent (Schild Kb=18 nM for human EP2), selective (10 to 
>500-fold over other prostanoid receptors as well as 38 other receptors, enzymes and 
channels), brain-permeant (brain/plasma = 0.8-1.6), orally available and with sufficient 
plasma half-life (1.6-2.5 hr) in mouse and rat to be useful for in vivo studies.17-19 Brief (2-3 
days) treatment with the EP2 antagonist beginning 2-4 h after SE onset, during the time 
in which neuronal COX-2 is induced, appeared to fully replicate the effects of neuron-
selective conditional COX-2 ablation. Thus, mice or rats treated with the EP2 antagonist 
showed neuroprotection, less neuroinflammation and blood-brain barrier (BBB) 
permeability function was preserved. Moreover, the typical development of a deficit in the 
novel object recognition test was prevented in rats treated briefly with the EP2 antagonist 
after SE onset.20 This suggests that much of the morbidity associated with COX-2 
induction after SE is mediated by the activation of EP2, and possibly EP1, by COX-2 
derived PGE2. Delayed inhibition of EP2 could therefore represent a viable adjunctive 
treatment for alleviating the deleterious consequences of SE. In studies of cultured 
microglia, EP2 has been shown to act as an immunomodulator of microglial activation, 
with much of its effects being mediated through ePAC (cAMP-regulated guanine 
nucleotide exchange factors) rather than protein kinase A.21; 22 Excessive EP2 activation 
can eventually kill activated microglia in vitro and thus might participate in resolution as 
well as generation of inflammation. 
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Terrone and colleagues provided evidence supporting that MAGL is a potential target for 
drug development in epilepsy, in particular for the treatment of drug-refractory SE.23 
MAGL is a key enzyme in the hydrolysis of the endocannabinoid 2-arachidonoylglycerol 
(2-AG) and represents the major brain source of arachidonic acid (AA) and 
eicosanoids.24 They showed that the severity and duration of benzodiazepine-refractory 
SE, and the consequent cell loss and cognitive deficits, were significantly reduced in 
mice treated with a potent and selective irreversible MAGL inhibitor, and these 
therapeutic effects were potentiated by the ketogenic diet (KD). Notably, when MAGL 
was inhibited in KD-fed mice, SE was virtually abolished with immediate effect. Moreover, 
KD itself, although not affecting SE, prevented the hippocampal cell loss. Based on these 
positive results, they are further evaluating the mechanisms of therapeutic action of 
MAGL inhibition to determine if it is mainly mediated by 2-AG accumulation, thereby 
activating CB1 receptors, or by reduction of arachidonic acid availability to COX-2, thus 
providing anti-inflammatory effects (unpublished observations).  
IL-1R1//TLR4 signaling, microRNAs, P2X7 receptors and immunoproteasome  
(A. Vezzani,  S. Bauer,  B. A. Norwood, E. Aronica, D. Henshall, M. Mishto) 
The activation of the IL-1R1 and TLR4 signaling pathways by their endogenous ligands 
IL-1β and HMGB1, respectively, is pivotal for the generation of neuroinflammatory 
responses during seizures or after epileptogenic injuries, and their pharmacological 
blockade or genetic inactivation results in powerful anticonvulsive effects.5 These 
pathways are concomitantly activated during epileptogenesis, thus likely requiring a 
rational drug combination for their effective blockade. Bauer and colleagues performed 
longitudinal cerebral microdialysis monitoring of hippocampal cytokine release in 
experimental epileptogenesis, detecting consistent elevations of IL-1β and Norwood 
provided evidence of endosomal Toll-like receptor dysregulation in experimental epilepsy 
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(unpublished observations). Vezzani and colleagues studied whether a combination of 
anti-inflammatory drugs targeting the ictogenic IL-1β-IL-1R1 and HMGB1-TLR4 pro-
inflammatory signals affects spontaneous seizure onset and disease progression in two 
rodent models of acquired epilepsy. They used two different schedules of intervention: 
male adult Sprague-Dawley rats exposed to electrical SE were given the drugs during the 
prodromal phase of epilepsy, while C57BL6 adult male mice exposed to intraamygdala 
kainate-induced SE were treated after the onset of the disease (i.e., after the first two 
unprovoked seizures). Rats were injected daily for 7 days with a combination of anakinra 
(IL-1 receptor antagonist), BoxA (HMGB1 antagonist) and ifenprodil (NR2B-NMDA 
receptor antagonist) starting 1 h post-SE. Mice were injected daily for 7 days with a 
combination of VX-765 (IL-1β biosynthesis inhibitor) and Cyanobacterial LPS (TLR4 
antagonist) starting after the onset of epilepsy in each mouse. EEG recording (24/7) was 
performed from SE induction until the onset of spontaneous seizures, and for an 
additional 4 weeks in the chronic epilepsy phase. The combined treatments blocked 
seizure progression occurring in this model over 3 months post-SE leading to a reduction 
in the frequency of spontaneous seizures by 70-90% in the chronic epilepsy phase both 
in rats and mice as compared to corresponding vehicle-treated SE-exposed animals 25. 
When drugs were given before the onset of epilepsy, they additionally reduced 
neurodegeneration in forebrain and improved memory deficits in epileptic animals. 
Similar therapeutic effects were attained when treating electrical SE-exposed rats with a 
combination of drugs targeting oxidative stress mechanisms (unpublished observations).  
The targeting of IL-1R/TLR4 signaling has been attempted also by epigenetic intervention 
with microRNAs (miRNAs). Molecular biology has been revolutionized by the discovery of 
these small regulatory molecules that regulate gene expression. Several miRNAs have 
been found in human brain to have crucial roles in a wide range of normal biological 
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processes, including inflammation.26; 27. In particular, Aronica and colleagues showed an 
upregulation of miRNAs involved in the modulation of the IL-1R/TLR pathway, including 
miR146a, miR21 and miR155, during epileptogenesis.28 These miRNAs were also shown 
to be deregulated in different human epilepsy-associated pathologies including 
hippocampal sclerosis, malformations of cortical development and glioneuronal tumors.29-
31 Interestingly, tumor and peritumoral miR146a expression was negatively correlated 
with frequency of seizures.30 The expression of miR21, miR146a and miR155 in 
astrocytes within epileptogenic brain lesions points to the role of these cell types as both 
source and targets of these miRNAs. IL-1β stimulation strongly induced miR146a 
extracellular release in human astrocytes in culture and IL-1β signaling was differentially 
modulated by overexpression of miR155 or miR146a, resulting in pro- or anti-
inflammatory effects, respectively. 31 It is likely that expression of miR146a in astrocytes 
may represent a homeostatic mechanism aimed at counteracting the inflammatory 
response triggered by either IL-1β or other pro-inflammatory miRNAs. 
To provide a preclinical proof-of-concept evidence of a therapeutic treatment targeting 
this miRNA, Vezzani, Aronica and colleagues tested the effect of a synthetic 
oligonucleotide analog of miR-146a in murine models of acute seizures and chronic 
epilepsy. Intracerebroventricular injection of a synthetic miR-146a mimic significantly 
reduced neuronal excitability and acute seizure susceptibility. Moreover, the mimic 
stopped the disease development when injected in mice after the epilepsy onset, and 
reduced cell loss and improved memory deficit when given shortly after the epileptogenic 
event. These therapeutic effects were similar to those attained with anti-inflammatory 
drug intervention against the IL-1R1 and TLR4 receptors, and were associated with 
broad modifications in immune/inflammatory pathways in the brain. 25 
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Another key driver of neuroinflammation is the P2X7 receptor, an ATP-gated ionotropic 
purinergic receptor predominantly expressed in microglia, and also in presynaptic nerve 
terminals. Henshall reported that activation of these receptors results in cell 
depolarization and activation of signaling pathways that promote microglial activation and 
inflammasome-mediated IL-1β release leading to acute and chronic neuroinflammation 
32; 33. Previous studies found increased expression of the P2X7 receptor in experimental 
and human epilepsy and antagonists of this receptor have been reported to reduce 
seizure severity in certain models of SE.34-36 In recent studies, a reporter mouse 
expressing enhanced green fluorescent protein driven by the P2rx7 gene promoter has 
been used to identify the cell types involved. These studies show that the receptor is 
expressed by neurons as well as microglia in mice that develop epilepsy after 
intraamygdala kainic acid-induced SE.37 Intracellular recordings and analysis of 
synaptoneurosomes indicated enhanced agonist-evoked and altered calcium responses 
in hippocampal neurons from epileptic mice. Increased P2X7 receptor levels were 
observed in hippocampus resected from patients with pharmacoresistant temporal lobe 
epilepsy, as well as in patients with focal cortical dysplasia.37; 38 Moreover, twice daily 
systemic injections of the centrally-available, potent and specific P2X7 receptor 
antagonist, JNJ-47965567 (30 mg/kg), significantly reduced spontaneous seizures during 
continuous video-EEG monitoring. Interestingly, the spontaneous seizure rate did not 
return to baseline during a relatively short monitoring after drug washout. The 
hippocampus of epileptic mice treated with the P2X7 receptor antagonist showed 
markedly reduced microgliosis and astrogliosis. These latest studies suggest that 
targeting the P2X7 receptor has anticonvulsant and possibly disease-modifying effects in 
experimental epilepsy.37 
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A potential novel target that was discussed by Mishto is the proteasome, the core of the 
ubiquitin proteasome system, which degrades the large majority of the cytoplasm 
proteins and thus it is involved in several metabolic pathways including synaptic protein 
metabolism.39 The incorporation of the three inducible subunits 1i, 2i, and 5i into 
newly formed proteasomes results in the generation of the so-called immunoproteasome. 
This proteasome isoform is normally induced during inflammation,  has altered 
polypeptide degradation dynamics compared to the standard proteasome isoform 40-42, 
and is endowed of pathophysiological functions related to immunity and inflammation 
responses.43 In healthy young human brain, the expression of the immunoproteasome is 
almost absent. 43 On the contrary, it is expressed in the brain of elderlies and patients 
with different neurological diseases with an inflammatory component such as Huntington 
disease, Alzheimer disease, multiple sclerosis 44-47, as well as with temporal lobe 
epilepsy and malformations of cortical development.48; 49 In agreement with the latter 
observations, the 5i immuno-subunit expression is induced also in experimental 
epilepsy, and its selective pharmacological inhibition reduced the incidence and delayed 
the occurrence of 4-aminopyridine-induced seizure-like events evoked in acute rat 
hippocampal/entorhinal cortex slices.50 These effects were stronger in slices obtained 
from epileptic vs normal rat brain, likely due to the prominent 5i subunit induction in 
neurons and glia in diseased tissue. TLR4 signaling activation is likely involved in the 
transcriptional induction of 5i, an effect which was independent on promoter 
methylation.50 The proteasome subunit expression is also induced by IL-1β in human 
astrocytes in vitro and is negatively regulated by treatment with the immunomodulatory 
drug rapamycin, an inhibitor of the mTOR pathway.49 How the immunoproteasome could 
have a pro-ictogenic effect is unknown. It could have either a specific role in synaptic 
density and as enhancer of inflammatory milieu as demonstrated for other neurological 
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diseases.47; 51 Of note, the immunoproteasome could regulate (neuro)inflammation not 
only as intracellular protease but also in the extracellular space. There, it could regulate 
pro-inflammatory functions of cytokines, as recently demonstrated for osteopontin in the 
multiple sclerosis context. 52 Therefore, the immunoproteasome might be considered as 
therapeutic target for pharmacoresistant epilepsies as it is already under investigation for 
cancers, Alzheimer disease and other diseases.47 
mTOR, TGF-beta and metalloproteinases as a targets for treatment   
(J. A. Gorter,  D. Kaufer, M.O. Poulter) 
Recent observations show that inhibition of the mTOR pathway affects SE-induced 
epileptogenesis in rat models of temporal lobe epilepsy.53; 54 Testing the hypothesis that 
the immunosuppressant rapamycin can also reduce brain inflammation after SE, Gorter 
reported that a 6 week treatment with rapamycin (6 mg/kg, i.p, 1st injection starting at 4 h 
post-SE induction) reduced seizure frequency during treatment and resulted in 
decreased neuronal death, mossy fiber sprouting and BBB leakage. Remarkably, 
hippocampal microglia and astroglia activation, which was used as an indicator of 
inflammation, was not altered compared to vehicle-injected rats, suggesting that the 
suppressive effect on seizures was not directly linked to reduction of inflammation.54 In 
order to get more insights into the time course of BBB damage and hippocampal 
inflammation, magnetic resonance imaging (MRI) was performed in rats using gadobutrol 
as a contrast agent, and, in a separate group of rats, RT-qPCR of hippocampal tissue 
was performed to measure markers of inflammation.54; 55 These experiments showed that 
both BBB leakage and inflammation were initially increased during rapamycin treatment 
in SE-rats compared to vehicle-treated rats, but recovered to a greater extent after the 
first week following SE in drug- than in vehicle-treated rats. The fact that inflammation 
markers were not significantly altered at 6 weeks after SE in rapamycin-treated rats as 
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compared to vehicle animals, implies that the drug reduces inflammation over time 
(unpublished observations). Moreover, the data suggest that rapamycin can modulate 
BBB integrity depending on the physiological condition of BBB during epileptogenesis. 
In order to find out whether rapamycin reduces seizure frequency via an anti-seizure 
effect or an anti-epileptogenic effect, additional experiments were performed.56 In the first 
experiment, rapamycin treatment was stopped 3 weeks post-SE and subsequent seizure 
development was monitored using hippocampal EEG recordings. It was found that the 
daily seizure reduction measured during treatment was lost after discontinuation of 
rapamycin. Nevertheless, the rate of seizure development with the “stop-treatment” 
protocol was slower than in rats that had received a vehicle treatment or historical post-
SE groups, suggesting a seizure-modifying effect of this treatment. (54) 
In the second experiment, rats that were treated with rapamycin during the chronic 
epilepsy phase, showed a reduction in the number of daily spontaneous seizures. 
Accordingly, inhibition of mTOR by rapamycin has been shown to suppress established 
chronic seizures in the pilocarpine rat model of epilepsy.57 Elimination of rapamycin from 
the bloodstream was extremely slow, with the drug being detectable still 1 month after 
the last injection in post-SE rats.56 Interestingly, in mice, elimination of rapamycin from 
the brain has been shown to be much slower than from blood/plasma.58  
Overall, these data suggest that the effect of rapamycin on seizure development could be 
due at least in part to a symptomatic seizure suppressing effect. During rapamycin 
treatment in post-SE rats, the rat’s body weight was strongly reduced vs vehicle, even 
when rapamycin dose was reduced (3 mg/kg). Moreover, brain size was also reduced by 
rapamycin, as detected by MRI (6 mg/kg). Thus, alternative mTOR inhibitors with a safer 
profile should be considered for therapeutic drug development in epilepsy.  
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Gorter, Kaufer, Friedman and colleagues have contributed to establish that BBB 
dysfunction occurs in epilepsy as in multiple neurological disorders including stroke and 
trauma. Consequently, blood-borne molecules enter the brain and induce an injury 
response leading to pathological changes.59-61 In particular, Kaufer reported evidence in 
collaboration with Friedman that albumin, the most abundant protein in the blood, serves 
as a signaling molecule to trigger the inflammatory injury response.59-62 Upon entering the 
brain after vascular damage, albumin is sensed by astrocytes, apparently via binding to 
transforming growth factor beta receptors (TGFβR), inducing the inflammatory TGFβ 
signaling pathway. This sets in motion a cascade of events that represent the earliest 
stages of post-traumatic pathology. Astrocytes become reactive and proliferate, releasing 
TGFβ1 and additional pro-inflammatory cytokines that amplify the injury response 
throughout the brain. In turn, subsequent widespread inflammatory signaling modulates 
neural physiology and network connectivity, causing changes that enhance neural 
excitability and ultimately lead to epilepsy. It has been shown that albumin activates 
TGFβR in astrocytes, causing a strong pro-inflammatory response and variety of 
changes within the neurovascular unit, including: reactive gliosis, reduced K+ and 
glutamate buffering, increased excitatory synaptogenesis and aberrant neurogenesis. 
These changes recapitulate the major hallmarks of epileptogenesis that have been 
extensively documented across animal models of epilepsy and in tissue samples from 
patients, to provide a “missing link” for how injury triggers these pathological changes. 
Using bioinformatics transcriptome analysis following five diverse clinical scenarios where 
BBB is disrupted (stroke, trauma, chemically-induced BBB disruption, and infusion of 
serum albumin or TGFβ), a common transcriptional signature was discovered dependent 
on albumin-induced activation of TGFβ signaling. Extracellular matrix (ECM) related-
genes emerged as a common transcriptional response, predicting consequent 
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degradation of ECM.62 Indeed, exposure of brain environment to albumin led to persistent 
degradation of perineuronal nets (PNNs, a protective ECM structure that provide synaptic 
stability and restrict reorganization of inhibitory interneurons) via activation of TGFβ 
signaling. 
Exposure of the brain environment to either albumin or TGFβ1 was sufficient to induce 
both epileptiform activity and delayed spontaneous seizures. Importantly, blocking TGF 
signaling prevented most albumin-induced hallmarks of epileptogenesis including TGF 
signaling, transcriptome-wide changes, synaptogenesis, neurogenesis, perineuronal net 
(PNN) degradation, hyperexcitability and seizures.59-61; 63; 64 Ongoing research evaluates 
the efficacy of multiple small molecules TGFβ signaling inhibitors in blocking or reversing 
the effects of BBB disruption on neuropathology, excitability, epilepsy development and 
cognitive functions. 
The integrity and stability of PNNs in a cortical network is essential for proper network 
function.65 Loss of interneuron synaptic stability and precise organization can lead to 
disruptions in the excitation/inhibition balance, a characteristic of epilepsy.66; 67 Recent 
research by Poulter's group supports the role of alterations to the GABAergic interneuron 
network in the piriform cortex after kindling-induced seizures.68 Immunohistochemistry 
was used to mark PNNs and interneuron nerve terminals in control and kindled tissue. 
PNNs were found to be significantly decreased around parvalbumin-positive interneurons 
after the induction of experimental epilepsy. Additionally, a layer-specific increase was 
detected in GABA release sites originating from calbindin, calretinin, and parvalbumin 
interneurons, implying that there is a re-wiring of the interneuronal network. This increase 
in release sites was matched by an increase in GABAergic postsynaptic densities. The 
observations suggest that the breakdown of the PNN could be due to the activity of 
matrix metalloproteinases (MMPs) and that the prevention of PNN breakdown may 
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reduce the rewiring of interneuronal circuits and suppress seizures. To test this 
hypothesis, doxycycline (DOX) a broad spectrum MMP inhibitor, was used to stabilize 
PNNs in kindled rats. DOX was found to prevent PNN breakdown, re-organization of the 
inhibitory innervation, and seizure genesis. These observations indicate that PNN 
degradation may be necessary for the development of seizures by facilitating interneuron 
plasticity and increased GABAergic activity. Another hypothesis is that activation of MMP 
after kindling may also be responsible for the conversion of pro-BDNF to BDNF. 
Furthermore, BDNF has been shown to induce the upregulation of the voltage gated 
potassium channel Kv1.6. This channel has also been shown to be upregulated in a 
kindling model causing a profound change in the excitability of parvalbumin positive 
interneurons.69 In order to see if MMP inhibition altered expression of BDNF, 
immunohistochemistry was performed in brain slices from kindled rats treated with DOX. 
Interestingly, BDNF expression was significantly less in this group in comparison to 
saline-treated kindled rats. It has also been observed that BDNF treatment of cultured 
cortical neurons increased the expression of Kv1.6. In kindled tissue DOX also 
normalized Kv1.6 expression.  
In sum, these data show that upregulation of MMP activity after kindling has wide ranging 
effects that alter innervation of interneurons as well as the excitability of a subpopulation 
neurons that are important regulators of network activity. 
Chemokines 
(P. Louboutin, M. Caleo, Y. Bozzi, E. Palma) 
These inflammatory molecules play a pivotal role in leukocyte migration across the BBB 
during neuroinflammation and other neuropathological processes.70; 71 When interacting 
with endothelial surfaces, some chemokines initiate integrin clustering, arrest leukocytes 
at sites of injury and guide them from vascular lumen into the brain. Once within the 
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brain, these cells, together with microglia and astrocytes, contribute to endothelial cell 
activation and further chemokine secretion. CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-
1β), and CCL5 (RANTES) induce chemotaxis of T lymphocytes and macrophages. In 
vitro CCL4 and CCL5 increase T cell adhesion to endothelial cells. CCL2 binding to 
CCR2 receptor stimulates efficient migration of monocytes/macrophages across brain 
vasculature, and CCR1 and CCR5 receptors facilitate CCL5-driven movement of blood 
mononuclear cells (PBMC) across brain endothelium. CCR5 is a member of the CC-
chemokine receptor family that binds several chemokines, including CCL3, CCL4 and 
CCL5. It is reportedly increased in epilepsy, as are its ligands. CCR5 is also expressed 
by microglia.  
Louboutin and colleagues71-73 investigated the role of CCR5 in a rat model of seizures 
provoked by intraperitoneal administration of kainic acid (KA). Four months before KA 
injection, adult rats were given femoral intramarrow inoculations of SV(RNAiR5-
RevM10.AU1), which carries an interfering RNA (RNAi) against CCR5, plus a marker 
epitope (AU1), or its monofunctional RNAi-carrying homolog, SV(RNAiR5). This 
treatment lowered expression of CCR5 in circulating PBMC. Controls received unrelated 
SV(BUGT) vector. In control rats, seizures increased the expression of CCR5 ligands 
MIP-1α and RANTES in the microvasculature and induced BBB leakage as well as CCR-
positive cells, inflammation, neuronal loss and gliosis in the hippocampi. Animals given 
either the bi- or the monofunctional vector were largely protected from KA-induced 
seizures, neuroinflammation and BBB damage, and exhibited a decreased production of 
MIP-1α and RANTES, as well as reduced neuron loss. Brain CCR5 mRNA was reduced 
in these rats. Rats receiving RNAiR5-bearing vectors showed far greater repair 
responses with increased neuronal proliferation. Thus, inhibition of CCR5 in circulating 
cells strongly protected rats from seizures, BBB leakage, CNS injury and inflammation, 
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and facilitated neurogenic repair. These results suggest that inhibition of CCR5 in 
circulating PBMC can decrease their interaction with endothelial cells, thus reducing 
leukocyte migration across the BBB, and consequently neuroinflammation and 
deleterious related events. 
The chemokine CCL2 is elevated in brain tissue from patients with pharmacoresistant 
epilepsy.74; 75 Caleo and colleagues74; 76 showed a crucial role for CCL2 and its receptor 
CCR2 in seizure control. Mice with spontaneous seizures and neuropathology 
resembling mesial temporal lobe epilepsy were systemically injected with 
lipopolysaccharide (LPS) to mimic a peripheral inflammatory challenge. LPS was found to 
increase seizure frequency and up-regulate the brain expression of many inflammatory 
proteins, including CCL2. To test the potential role of CCL2 in seizure exacerbation, 
either a CCL2 transcription inhibitor (bindarit) or a selective antagonist of the CCR2 
receptor (RS102895) was administered systemically. Interference with CCL2 signaling 
potently suppressed LPS-induced seizure worsening.76 Intracerebral administration of 
anti-CCL2 antibodies also abrogated LPS-mediated seizure enhancement in chronically 
epileptic animals. These results reveal that CCL2 is a key mediator that link peripheral 
inflammation with neuronal hyperexcitability.  
Palma reported that cytokines and chemokines can both influence GABAA receptor 
function, although they can exert opposite effects on neuronal synaptic transmission. For 
example the chemokine fractalkine (CX3CL1) is responsible for a positive modulation of 
GABAA receptor in human TLE brain because it slows the GABAA use-dependent 
desensitization (i.e. rundown).75 Differently, IL-1β was found to reduce GABAA-mediated 
current amplitude by activating IRAK1 and protein kinase C.77 In both cases, the effects 
on GABA currents were intrinsic characteristic of the epileptic brain tissue, since such 
effects were absent in non-epileptic controls. This observation is explained, at least in 
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part, by an upregulation of the cytokine/chemokine receptors. Interestingly, while in the 
fractalkine case the receptor’s upregulation may represent an attempt to reduce changes 
induced by epileptic insults, the IL-1β pathway actively contributes to ictogenesis through 
the impairment of GABA-mediated neurotransmission.77; 78 Altogether, these data 
indicate that GABAergic system is significantly modulated by inflammatory mediators 
released in epileptic foci, thus opening a wide scenario of novel therapeutic opportunities 
for controlling neuronal network hyperexcitability in epileptic patients.  
The role of peripheral immune cells 
(S. Koh, R. Dingledine) 
Koh’s laboratory has pioneered the characterization of inflammatory cell infiltrates in the 
surgically removed fresh brain samples from pediatric patients in search for novel 
therapeutic targets. They used an unbiased flow cytometric analysis of inflammatory 
leukocytes in resected brain tissues from pediatric patients with genetic (focal cortical 
dysplasia, FCD) or acquired (encephalomalacia) epilepsy. They detected functionally 
activated lymphocytes within the epileptogenic lesion of both patients and experimental 
animals. Brain infiltration of inflammatory myeloid cells and memory CD4+ and CD8+ T 
cells was observed (unpublished observations).77 This is in line with previous 
observations in both focal cortical dysplasia type IIb and cortical tubers in Tuberous 
Sclerosis Complex patients.78-81 In particular, T cells are concentrated in the 
epileptogenic lesion and their numbers positively correlate with disease severity, whereas 
numbers of regulatory T cells (Tregs) inversely correlate (unpublished observations). T 
cell-deficient mice systemically injected with KA showed reduction in SE severity while 
Treg depletion heightened seizure severity. These data support a role for peripherally-
derived innate and adaptive immune responses in the pathogenesis of intractable 
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pediatric epilepsy favoring the clinical development and testing of novel 
immunotherapeutic drugs.  
Steroids that are known for their anti-inflammatory and immuno-suppressive properties 
have shown efficacy in many types of drug-resistant epilepsies. However, the severe side 
effects of steroids have prevented long-term or widespread use of these drugs. Koh and 
colleagues used a two-hit model of epileptogenesis to design novel therapies to treat 
epilepsy using immunomodulatory approaches independent of broadly-acting 
immunosuppressive agents. They hypothesize that dampening ongoing inflammation in 
the brain could effectively reduce unprovoked recurrent seizures in the absence of 
systemic immunosuppression. Previous work by Miller’s lab documented the success of 
using biodegradable nanoparticles formulated from the FDA-approved biopolymer 
poly(lactide-co-glycolide) (PLG) to treat a variety of inflammatory immune-mediated 
disease in animal models.82 Miller’s lab has also demonstrated that supplementation of 
autologous natural regulatory T cells (nTregs) significantly reduces disease severity in 
multiple animal models of multiple sclerosis 79; 80. In the two-hit model of early-life 
seizures, treatment with PLG nanoparticles induced leukocyte sequestration in the 
spleen, thereby reducing their brain infiltration, and prevented the priming effect of early-
life seizures for heightened seizure susceptibility in adulthood. Similarly, infusion of 
nTregs after the first seizure blocked the priming effect of early-life seizures (unpublished 
observations). Inhibition of long-term effects of early seizures priming was attained also 
by directly blocking inflammatory microglia in the hippocampus with minocycline 81. The 
characterization of the adaptive immunity responses in epilepsy and the effects of 
restriction of brain infiltration by inflammatory leukocyte subsets on seizures represent 
major steps forward in our understanding of epilepsy pathophysiology. 
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Dingledine and colleagues examined the cellular components of innate immune 
inflammation in the early days following kainate- or pilocarpine-induced SE in adult mice 
by discriminating microglia versus brain-infiltrating monocytes.86 CCR2+ monocytes 
invade hippocampus between one and three days after SE. In contrast, at odds with 
early-life seizures only occasional CD3+ T-lymphocytes were encountered three days 
post-SE in adult animals. The chemokine CCL2, a ligand for CCR2, was expressed in 
perivascular macrophages and microglia one day after SE. Four days after SE the 
induction of the pro-inflammatory cytokine IL-1β was greater in Fluorescence activated 
cell sorting (FACS) -isolated microglia than in brain monocytes. However, in WT naive 
mice the mRNA levels of IL-1β were 125-fold higher in circulating blood monocytes than 
in resting microglia, and TNFα levels were 486-fold greater in blood monocytes. Ccr2 KO 
mice displayed greatly reduced monocyte recruitment into brain and reduced levels of the 
pro-inflammatory cytokine IL-1β in hippocampus after SE. This was explained by high 
level of the cytokine in circulating monocytes in wild-type mice which were prevented 
from entering the brain after SE in Ccr2 KO mice. These findings indicate that microglia 
and monocytes respond differently to SE. Whereas brain-invading monocytes show little 
induction of IL-1β and TNFα mRNA in response to SE, both IL-1β and CCL2 are 
significantly induced in activated microglia. However, these results also indicate that the 
level of IL-1β and TNFα in circulating monocytes is much higher than that of activated 
microglia. Therefore, preventing monocyte recruitment into the brain may reduce the 
extent of neuroinflammation. Mice with impaired monocyte recruitment showed 
accelerated weight regain, reduced BBB leakage, and attenuated neuronal damage 
following SE.82 These findings identify brain-infiltrating monocytes as a myeloid cell 
subclass that contributes substantially to the extent of neuroinflammation and morbidity 
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after SE. Inhibiting brain invasion of CCR2+ monocytes could represent a viable method 
for alleviating the deleterious consequences of SE.  
Conclusion and Future directions 
Several inflammatory targets and pathways discussed above provide examples of new 
potential avenues for future therapeutic approaches in epilepsy. Importantly, these 
studies indicate that immunomodulatory treatments alone might not be sufficient to 
counteract epileptogenesis efficiently, rather that it is likely necessary to interfere with the 
complex pathophysiological underpinnings of epileptogenesis at multiple levels and in 
various cell types (e.g., with drug combinations or complementary treatment 
approaches). miRNAs as master regulators of immune responses could also represent 
interesting targets for therapy. miRNA formulation, delivery methods into the CNS for 
bypassing the BBB and specifically targeting the seizure focus remain major challenges 
in the clinical translation.  
Despite the achievements and significant progress reported during the IIE2016 meeting, 
a major challenge is represented by the translation of these experimentally successful 
anti-ictogenic or disease modifying targets into clinically effective human therapies. This 
translation requires intense and collaborative efforts by both preclinical and clinical 
scientists as well as industry partners. Future success of drug development should be 
based on a more coordinated experimental and clinical trial designs guided by relevant 
biomarkers that may be used to monitor epileptogenesis.  
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Figure Legend 
 
Figure 1. Schematic representation of the cascade of inflammatory processes in 
which neurons, astrocytes, microglia  and endothelial cells are involved. 
Several inflammatory targets  have been validated in experimental models (i.e. 
cyclooxygenase-2, prostaglandin EP2 receptor, Interleukin‐1 HMGB1/Toll‐like receptor 
signaling, P2X7 receptor, immunoproteasome, mTOR, TGF-beta, metalloproteinases 
(MMP), chemokines).  The complement activation (not shown) could also contribute to a 
sustained inflammatory response98,99, deserving further investigation as potential  target 
of therapy.  
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Table 1. Overview of targets and treatments validated in experimental models 
Target/pathway Experimental models Treatment/drugs Effect References 
Cox-2  Pilocarpine-induced SE 
Sprague-Dawley rats 
Electrically-induced SE 
Sprague-Dawley rats 
Electrically-induced SE 
Pilocarpine (+LPS)-
induced SE  
Sprague-Dawley rats 
Wistar rats  
Absence seizures in 
WAG/Rij rats 
Pilocarpine-induced SE 
C57BL/6 mice 
COX-2 inhibitor 
celecoxib 
COX-2 inhibitor 
SC58236 
COX-2 inhibitor 
parecoxib 
COX-2 inhibitor  
CAY 10404 
COX-2 inhibitor 
etericoxib 
COX-2 neuronal 
conditional KO 
C57BL/6 mice 
Antiepileptogenic, 
disease-modifying  
No antiepileptogenic  
Disease-modifying  
No antiepileptogenic  
Disease-modifying   
9 
10 
11 
12 
13 
8 
Cox 2 +  IL-1 
 
Pilocarpine (+LPS)-
induced SE 
Wistar rats 
 
COX-2 inhibitor CAY 
10404+ recombinant 
Interleukin-1 antagonist  
Disease-modifying   12 
EP2/ PGE2 receptor Organophosphorus 
induced  SE 
Sprague-Dawley rats 
Pilocarpine-induced SE 
C57BL/6 mice 
EP2 competitive 
antagonist TG6-10-1 
EP2 competitive 
antagonist TG6-10-1 
Disease-modifying   
Disease-modifying 
19; 20 
18 
Monoacylglycerol 
lipase 
Intraamygdala  kainic 
acid induced  SE  
C57BL/6 mice 
CPD-4645 (MAGL 
inhibitor)  
Disease-modifying   Terrone, Vezzani et 
al.,  unpublished 
observations 
IL-1
 
Bicuculline induced 
seizures C57BL/6 mice 
Pilocarpine-induced SE 
Sprague-Dawley rats  
Rapid kindling model 
Electrically-induced SE/ 
pilocarpine-induced SE 
Wistar rats/Sprague-
Dawley rats 
 
Genetic absence 
epilepsy (GAERS rats); 
kainic acid–induced 
seizures; electrically-
induced SE/ pilocarpine-
induced SE;  
Human recombinant IL-1 
receptor antagonist 
(anakinra) 
 
 
 
 
VX-765 (caspase-1 
inhibitor) 
Anti-convulsive 
Anti-convulsive 
Antiepileptogenic  
No antiepileptogenic or  
disease-modifying   
 
Anti-convulsive/ 
Antiepileptogenic  
 
 
83 
84 
85 
86 
86-90 
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 kindling model 
Sprague-Dawley rats 
 
TLR4 or HMGB1 Kainic acid–induced 
seizures 
C57BL/6 mice 
 
 HMGB1 (BoxA) and TLR4 
(Lps-Rs) antagonists 
Anti-convulsive  91 
IL-1HMGB1
 
Kainic acid–induced 
seizures 
C57BL/6 mice 
Anakinra (IL-1 receptor 
antagonist), BoxA 
(HMGB1 antagonist) 
Disease-modifying   25 
IL-1/miR146 Kainic acid–induced 
seizures 
Intraamygdala  kainic 
acid induced  SE   
C57BL/6 mice 
miR146a-mimic Anti-convulsive and 
Disease-modifying   
25; 92; 93. 
P2X7 receptor intra-amygdala kainic 
acid-induced status 
epilepticus 
C57BL/6 mice 
P2X7 receptor antagonist 
JNJ-47965567 
Disease-modifying  37 
Immunoproteasome 4-aminopyridine-
induced seizure-like 
events/Wistar rats 
5i immuno-subunit 
inhibitor
Anti-convulsive 50 
mTOR Kainic acid–induced SE 
Electrically-induced SE/ 
Kainic acid–induced SE 
Rapamycin Anti-convulsive/ 
Antiepileptogenic  
Anti-convulsive and 
Disease-modifying   
94 
54-56 
TGF rat model of vascular 
injury/ albumin-
induced seizures 
Wistar rats 
 
Losartan (TGF-β 
signaling blocker ) 
 
Anti-convulsive/ 
Antiepileptogenic  
 
64 
Metalloproteinases kindling-induced 
seizures  
Sprague-Dawley rats 
 
 
Doxycycline  (broad 
spectrum MMP inhibitor) 
Anti-ictogenic  68 
Chemokines Kainic acid–induced SE 
Sprague-Dawley rats 
Kainic acid–induced SE + 
LPS 
C57BL/6 mice 
RNAi against CCR5 
CCR2 antagonist 
(RS102895); transcription 
inhibitor (bindarit) 
Disease-modifying   
Anti-convulsive 
71 
76 
Peripheral immune 
cells 
Acquired  and genetic  
epilepsy models 
C57BL/6 mice 
PLG nanoparticles 
combined with 
autologous natural 
regulatory T cells 
Inhibiting brain invasion 
of CCR2+ monocytes 
Effects on 
epileptogenesis: to be   
determined 
Effects on 
epileptogenesis: to be   
determined 
Koh et al., 
unpublished 
observations 82 
SE, status epilepticus. Celecoxib, Parecoxib, Etoricoxib: COX-2 inhibitors, nonsteroidal anti-inflammatory drug  
used for pain management; SC5823 , CAY 10404:  COX-2 inhibitors with anti-inflammatory properties. Human 
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recombinant IL-1 receptor antagonist (anakinra): nonsteroidal anti-inflammatory drug  used to treat 
autoinflammatory diseases. TG6-10-1: prostaglandin E2 receptor 2 competitive antagonist with anti-
inflammatory properties. CPD-4645: monoacylglycerol lipase (MAGL) inhibitor with anti-inflammatory 
properties. VX-765: caspase-1 inhibitor (ICE/caspase-1 subfamily) with anti-inflammatory properties. BoxA, 
High-Mobility Group Box-1 (HMGB1) antagonist of Lps-Rs,  toll-like receptor 4 (TLR4) antagonist with anti-
inflammatory properties. miR146a-mimic: small, chemically modified double-stranded RNA that mimic 
endogenous miR146a with anti-inflammatory properties. JNJ-47965567: high affinity P2X7 antagonist with 
anti-inflammatory properties. 5i/ LMP7 immuno-subunit inhibitor: immunomodulatory properties. 
Rapamycin: mammalian target of rapamycin (mTOR) inhibitor with immunosuppressant 
/immunomodulatoryproperties, originally applied as an immunosuppressant, blocking T-cell activation, and 
has been in use to prevent kidney graft rejection; mTOR inhibithors are used in the cancer therapy 95 and in the 
management  of patient with Tuberous Sclerosis Complex (TSC;96). Losartan: selective, competitive angiotensin 
II receptor type 1 a commonly used anti-hypertensive, also shown to antagonize TGF-β signaling. Doxycycline:  
a broad-spectrum antibiotic of the tetracycline used to treat bacterial infections, which has been shown to  
have anti-inflammatory properties and to act as broad spectrum metalloproteinases (MMP) inhibitor. CCR5 
(CC Chemokine Receptor). RS102895: a spiropiperidine compound that acts as a  CCR2 (CC Chemokine 
Receptor) antagonist with anti-inflammatory properties. Bindarit: inhibitor of CCL2 synthesis with anti-
inflammatory properties. Biodegradable nanoparticles formulated from the FDA-approved biopolymer 
poly(lactide-co- glycolide) (PLG)  with anti-inflammatory properties. 
 
 34 
 
34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Neuroinflammatory targets validated in experimental models 
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